Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124817245 | 12481724 | 5 | F | 20160606 | 20160829 | 20160620 | 20160831 | EXP | US-BAYER-2016-110864 | BAYER | 68.00 | YR | E | M | Y | 0.00000 | 20160831 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124817245 | 12481724 | 1 | PS | NEXAVAR | SORAFENIB | 1 | 400 MG, BID | BXH8GZ3 | 21923 | 400 | MG | FILM-COATED TABLET | BID | ||||||
| 124817245 | 12481724 | 2 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, QD (1 TABLET EACH EVENING) | 21923 | 200 | MG | FILM-COATED TABLET | QD | ||||||
| 124817245 | 12481724 | 3 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, QD (2 TABLET EACH EVENING) | 21923 | 400 | MG | FILM-COATED TABLET | QD | ||||||
| 124817245 | 12481724 | 4 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, QD (1 TABLET EACH EVENING) | 21923 | 200 | MG | FILM-COATED TABLET | QD | ||||||
| 124817245 | 12481724 | 5 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 200 MG, QOD | 21923 | 200 | MG | FILM-COATED TABLET | QOD | ||||||
| 124817245 | 12481724 | 6 | SS | NEXAVAR | SORAFENIB | 1 | Oral | 400 MG, UNK | BXH8GZ3 | 21923 | 400 | MG | FILM-COATED TABLET | ||||||
| 124817245 | 12481724 | 7 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 0 | ||||||||||||
| 124817245 | 12481724 | 8 | C | MORPHINE | MORPHINE | 1 | 0 | ||||||||||||
| 124817245 | 12481724 | 9 | C | LISINOPRIL. | LISINOPRIL | 1 | 0 | ||||||||||||
| 124817245 | 12481724 | 10 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 124817245 | 12481724 | 11 | C | DILAUDID | HYDROMORPHONE HYDROCHLORIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124817245 | 12481724 | 1 | Hepatocellular carcinoma |
| 124817245 | 12481724 | 2 | Colon cancer |
| 124817245 | 12481724 | 3 | Hepatocellular carcinoma |
| 124817245 | 12481724 | 4 | Hepatocellular carcinoma |
| 124817245 | 12481724 | 5 | Hepatocellular carcinoma |
| 124817245 | 12481724 | 6 | Hepatocellular carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124817245 | 12481724 | HO |
| 124817245 | 12481724 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124817245 | 12481724 | Abdominal pain | |
| 124817245 | 12481724 | Blister | |
| 124817245 | 12481724 | Diarrhoea | |
| 124817245 | 12481724 | Fatigue | |
| 124817245 | 12481724 | Hypertension | |
| 124817245 | 12481724 | Hypoaesthesia | |
| 124817245 | 12481724 | Micturition disorder | |
| 124817245 | 12481724 | Oral mucosal blistering | |
| 124817245 | 12481724 | Palmar-plantar erythrodysaesthesia syndrome | |
| 124817245 | 12481724 | Portal vein thrombosis | |
| 124817245 | 12481724 | Pyrexia | |
| 124817245 | 12481724 | Rash | |
| 124817245 | 12481724 | Urinary tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124817245 | 12481724 | 1 | 20160603 | 2016 | 0 | |
| 124817245 | 12481724 | 2 | 20160705 | 20160711 | 0 | |
| 124817245 | 12481724 | 3 | 20160712 | 201607 | 0 | |
| 124817245 | 12481724 | 4 | 201607 | 2016 | 0 | |
| 124817245 | 12481724 | 5 | 2016 | 2016 | 0 | |
| 124817245 | 12481724 | 6 | 2016 | 20160815 | 0 |